Chondrial Therapeutics, Inc., the Bala Cynwyd-based biopharmaceutical company, has raised $25.8 million to develop treatment for mitochondrial disorders.

THE INQUIRER, phillynews.com. Sam Wood, Updated: May 23, 2019
Chondrial Therapeutics, Inc., the Bala Cynwyd-based biopharmaceutical company, has raised $25.8 million to develop treatment for mitochondrial disorders.
Chondria’s FA therapy has the much-coveted orphan drug designation from the FDA. Chondrial will file an Investigational New Drug application in the next couple of months and go into trials “almost immediately”.

Chondrial Therapeutics, Inc., the Bala Cynwyd-based biopharmaceutical company, has raised $25.8 million to develop treatment for mitochondrial disorders.